Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-κB subunit RelA

Anneke D. van Dijk, Fieke W. Hoff, Yihua Qiu, Robert B. Gerbing, Alan S. Gamis, Richard Aplenc, E. Anders Kolb, Todd A. Alonzo, Soheil Meshinchi, Gaye N. Jenkins, Eveline S.J.M. de Bont, Steven M. Kornblau*, Terzah M. Horton

*Corresponding author for this work

    Research output: Contribution to journal › Article › Academic › peer-review

    6 Citations (Scopus)
    198 Downloads (Pure)

    Fingerprint

    Dive into the research topics of 'Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-κB subunit RelA'. Together they form a unique fingerprint.

    Keyphrases

    Medicine and Dentistry